ALXN, VRTX, REGN, BIIB And CELG, 5 Drugs Stocks Pushing The Industry Lower

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 63 points (0.4%) at 15,199 as of Monday, July 8, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,878 issues advancing vs. 1,083 declining with 93 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 1.0%. Top gainers within the industry include Allergan ( AGN), up 2.8%, Sanofi ( SNY), up 1.1%, Teva Pharmaceutical Industries ( TEVA), up 0.9%, AstraZeneca ( AZN), up 0.7% and GlaxoSmithKline ( GSK), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $2.39 (-2.5%) to $94.06 on average volume. Thus far, 587,254 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $94.06-$97.00 after having opened the day at $97.00 as compared to the previous trading day's close of $96.45.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.7 billion and is part of the health care sector. Shares are up 2.9% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk